Genetics may help explain why results from weight-loss jabs vary, say scientists科学家表示，基因可能有助于解释为何减重针的效果因人而异
完整音频预览
0:00
0:00
#1
New clinical research suggests that gene variations may partly account for why weight-loss treatments work remarkably well for some patients yet prove less effective for others.
新的临床研究显示，基因变异可能在一定程度上解释了为什么减重疗程对某些患者效果显著，但对其他患者则效果较差。
#2
Scientists have identified two specific genetic variants linked to gut hormone pathways that appear to influence both treatment outcomes and side-effects associated with popular obesity medications.
科学家已鉴定出两个与肠道激素途径相关的特定基因变异，这些变异似乎会影响治疗效果以及与热门肥胖药物相关的副作用。
#3
The findings, published in the journal Nature, draw on data from nearly 28,000 patients prescribed GLP1 receptor agonist drugs.
这项发表于《自然》期刊的研究结果，利用了近 28,000 名被开立 GLP1 受体激动剂药物患者的数据。
#4
These medications, including semaglutide, marketed as Wegovy, and tirzepatide, sold under the brand name Mounjaro, mimic natural gut hormones that regulate appetite and insulin release.
这些药物，包括以 Wegovy 为名销售的司美格鲁肽 (semaglutide)，以及以品牌名称 Mounjaro 贩售的替泽帕肽 (tirzepatide)，模仿了调节食欲和胰岛素释放的天然肠道激素。
#5
Millions of people worldwide now rely on such drugs to manage obesity, yet the reasons behind individual variation in response have long remained elusive.
全球数百万人现在依赖此类药物来控制肥胖，然而，反应中个体差异背后的原因长期以来一直难以捉摸。
#6
Researchers from 23andMe, a nonprofit medical research institute, reported that one variant, known as rs10305420, was associated with slightly greater weight loss among carriers.
来自非营利医学研究机构 23andMe 的研究人员报告称，一种名为 rs10305420 的变体与携带者体重减轻幅度略大有关。
#7
Another variant, rs1800437, was linked to nausea and vomiting in patients taking tirzepatide, though it bore no significant correlation with the amount of weight lost.
另一种变体 rs1800437 与服用替泽帕肽（tirzepatide）患者出现的恶心和呕吐有关，尽管它与体重减轻的量并无显著相关性。
#8
These discoveries underscore how subtle genetic differences may shape an individual's physiological response to medication.
这些发现强调了细微的基因差异如何可能塑造个人对药物的生理反应。
#9
Should these preliminary findings be validated by larger studies, they could pave the way for a more personalised approach to obesity treatment.
如果这些初步发现能通过更大规模的研究得到证实，它们将能为更个性化的肥胖治疗方式铺平道路。
#10
Clinicians have long emphasised that a one-size-fits-all strategy rarely yields optimal outcomes in chronic disease management.
临床医生长期以来一直强调，一律适用的策略在慢性病管理中鲜少能产生最佳成效。
#11
Were physicians able to screen patients' genetic profiles before prescribing weight-loss drugs, they might anticipate who would benefit most and who might experience adverse reactions.
若医生能在开具减重药物前筛查患者的基因图谱，他们或许就能预见谁会获益最多，以及谁可能会产生不良反应。
#12
Nonetheless, experts have cautioned that the overall impact of genetics on drug response appears modest at this stage.
尽管如此，专家们警告说，遗传学对药物反应的整体影响在现阶段看来并不明显。
#13
The interplay between genetic predisposition, lifestyle factors, and metabolic health remains extraordinarily complex.
基因倾向、生活方式因素与代谢健康之间的相互作用仍然极其复杂。
#14
Further large-scale studies will be indispensable if researchers are to develop reliable genetic screening tools for clinical use in the foreseeable future.
若研究人员要在可预见的未来开发出可靠的基因筛检工具，进一步的大规模研究将是不可或缺的。